Trial · NCT04433481
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with complete recanalization of thrombus in both groups. | 1 year | |
| Secondary | Number of participants with partial recanalization of thrombus in both groups. | 1 Year | |
| Secondary | Number of participants with improvements in Child-Turcotte-Pugh (CTP) in both groups. | 6 months | |
| Secondary | Number of participants with improvements in Child-Turcotte-Pugh (CTP) in both groups. | 1 year | |
| Secondary | Improvements in Model for End Stage Liver Disease (MELD) Score in both groups | 6 months | MELD score ranges from 6 to 40. |
| Secondary | Improvements in Model for End Stage Liver Disease (MELD) Score in both groups | 1 Year | MELD score ranges from 6 to 40. |
| Secondary | Number of participants with prevention of secondary decompensation in both groups | 1 Year | |
| Secondary | Adverse Events in both groups | 1 year | |
| Secondary | To study the changes in coagulation parameters by ROTEM(Rotational Thrombo Elastometry) analysis which includes CFT(clot formation time). | 6 Months | |
| Secondary | To study the changes in coagulation parameters by ROTEM(Rotational Thrombo Elastometry) analysis which includes CFT(clot formation time). | 12 Months | |
| Secondary | Number of participants with reduction in clinical complications in patients with PVT in both groups | 3 Months | |
| Secondary | Number of participants with reduction in clinical complications in patients with PVT in both groups | 6 Months | |
| Secondary | Number of participants with reduction in clinical complications in patients with PVT in both groups | 12 Months | |
| Secondary | To study the number of participants developing reoccurrence of PVT after treatment with Dabigatran for 12 months by Ultrasound Doppler of splenoportal venous system. | 12 months | |
| Secondary | To determine predictors for recurrence of PVT in patients with cirrhosis. | 1 year | |
| Secondary | To study the predictors of development of PVT in the population of cirrhosis patients screened who did not have PVT at the initiation of the study, for the development of new PVT over the period of the study | 1 year |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04433481/registered